Antiviral treatment of COVID-19: An update.

@article{Yavuz2021AntiviralTO,
  title={Antiviral treatment of COVID-19: An update.},
  author={Serap Simşek Yavuz and Feride Ipek Komsuoğlu Çelikyurt},
  journal={Turkish journal of medical sciences},
  year={2021}
}
Currently there is not an effective antiviral treatment for COVID-19, but a large number of drugs have been evaluated since the beginning of the pandemic and many of them have been used for the treatment of COVID-19 despite the preliminary or conflicting results of the clinical trials. We aimed to review and summarize all of the current knowledge on the antivirals for COVID-19. There are 2 main drug groups for SARS-CoV-2: Agents that target proteins or RNA of the virus or interfere with… 
Current and emerging immunomodulators for treatment of SARS-CoV2 infection (COVID-19)
  • M. McCarthy
  • Medicine, Biology
    Expert opinion on pharmacotherapy
  • 2022
TLDR
Current therapeutic approaches, including the use of immunomodulators such as corticosteroids, interleukin inhibitors, kinase inhibitors, fluvoxamine, and ivermectin are examined, and the ways that these therapies and others may be used to treat COVID-19 in the future are explored.
Mechanism of Action of Small-Molecule Agents in Ongoing Clinical Trials for SARS-CoV-2: A Review
TLDR
The candidate small-molecule anti-SARS-CoV-2 drugs in ongoing clinical trials are reviewed, with a major focus on their mechanisms of action in an attempt to provide useful insight for further research and development of small- molecule compounds against SARS- CoV- 2 infection.
Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir
Entrectinib - a SARS-CoV-2 inhibitor in Human Lung Tissue (HLT) cells
TLDR
It is found that part of the antiviral action of entrectinib is mediated by a non-specific mechanism, likely occurring at the viral membrane level, which could provide ent rectinib with protection against the development of drug resistance by emerging SARS-CoV-2 variants.
Human Cell Organelles in SARS-CoV-2 Infection: An Up-to-Date Overview
Since the end of 2019, the whole world has been struggling with the life-threatening pandemic amongst all age groups and geographic areas caused by Severe Acute Respiratory Syndrome Coronavirus
Entrectinib—A SARS-CoV-2 Inhibitor in Human Lung Tissue (HLT) Cells
TLDR
By combining virtual screening with in vitro pseudovirus assays and antiviral assays in Human Lung Tissue (HLT) cells, entrectinib is identified as a potential antiviral drug.
Target-Based Virtual Screening and LC/MS-Guided Isolation Procedure for Identifying Phloroglucinol-Terpenoid Inhibitors of SARS-CoV-2
TLDR
This study has led to the development of a target-based virtual screening method for exploring the potency of natural products and for identifying natural bioactive compounds for possible COVID-19 treatment.